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Abstract
Introduction: In the present study, we analysed in detail nuclear autoantibodies and their associations in systemic
sclerosis (SSc) patients included in the German Network for Systemic Scleroderma Registry.
Methods: Sera of 863 patients were analysed according to a standardised protocol including immunofluorescence,
immunoprecipitation, line immunoassay and immunodiffusion.
Results: Antinuclear antibodies (ANA) were detected in 94.2% of patients. In 81.6%, at least one of the
autoantibodies highly associated with SSc or with overlap syndromes with scleroderma features was detected, that
is, anti-centromere (35.9%) or anti-topoisomerase I (30.1%), followed in markedly lower frequency by antibodies to
PM-Scl (4.9%), U1-ribonucleoprotein (U1-RNP) (4.8%), RNA polymerases (RNAPs) (3.8%), fibrillarin (1.4%), Ku (1.2%),
aminoacyl-transfer RNA synthetases (0.5%), To (0.2%) and U11-RNP (0.1%). We found that the simultaneous
presence of SSc-associated autoantibodies was rare (1.6%). Furthermore, additional autoantibodies were detected in
55.4% of the patients with SSc, of which anti-Ro/anti-La, anti-mitochondrial and anti-p25/p23 antibodies were most
frequent. The coexistence of SSc-associated and other autoantibodies was common (43% of patients). SSc-
associated autoantibodies disclosed characteristic associations with clinical features of patients, some of which
were previously not acknowledged.
Conclusions: This study shows that five autoantigens (that is, centromere, topoisomerase I, PM-Scl, U1-RNP and
RNAP) detected more than 95% of the known SSc-associated antibody responses in ANA-positive SSc patients and
characterise around 79% of all SSc patients in a central European cohort. These data confirm and extend previous
data underlining the central role of the determination of ANAs in defining the diagnosis, subset allocation and
prognosis of SSc patients.
Keywords: systemic sclerosis, scleroderma, autoantibodies, antinuclear antibodies
* Correspondence: mierau.rmn@t-online.de
1Laboratory at Rheumaklinik Aachen, Hauptstrasse 21, Aachen, D-52066,
Germany
Full list of author information is available at the end of the article
Mierau et al. Arthritis Research & Therapy 2011, 13:R172
http://arthritis-research.com/content/13/5/R172
© 2011 Mierau et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Introduction
Autoantibodies targeting characteristic nuclear antigens
are one of the hallmarks of systemic sclerosis (SSc)
[1-3]. The occurrence of different antinuclear antibodies
(ANAs) is associated with distinct disease subtypes and
with differences in disease severity, including extent of
skin involvement, internal organ manifestation and
prognosis. Although the current SSc criteria of the
American College of Rheumatology [4] do not include
t h ep r e s e n c eo fA N A s ,T h ed e t e c t i o no fs c l e r o d e r m a -
associated antibodies may be a valuable tool in the diag-
nosis of patients with very early SSc or only subtle
symptoms [5,6]. For instance, in a recent study of
patients with Raynaud’s phenomenon, the presence of
ANAs (adjusted HR = 5.67) and SSc-associated antibo-
dies (HR = 4.7) was the strongest independent predictor
of definite SSc [6]. Some of the autoantibodies in SSc
are regarded as disease-specific and can be correlated
with genetic, demographic, diagnostic, clinical and prog-
nostic aspects of the disease [1,3]. Therefore, autoanti-
bodies are pivotal tools in the diagnosis of SSc by
helping clinicians make decisions whether to perform
further, more detailed and efficient diagnostic proce-
dures, as well as decisions addressing disease
management.
For frequently occurring antibodies such as anti-cen-
tromere (ACA) and anti-topoisomerase I (ATA), reliable
detection systems based on ELISA or other binding tests
have been developed. Other antibodies (that is, to fibril-
larin, RNA polymerases (RNAPs) and so on) are not
identified by common test procedures, but rather by
laboratories able to perform sophisticated procedures to
confirm the results on the basis of more than one inde-
pendent method. Even for the most common autoanti-
bodies, the choice of the detection method used is
critical to the sensitivity and specificity of the results
and hence their diagnostic value [7].
Researchers in numerous studies have examined the
presence of antibodies to single predefined antigens in
SSc and their clinical associations, whereas many of the
investigators who have comprehensively examined large
SSc patient cohorts have often restricted their autoanti-
body analyses to the most common SSc antibodies,
ACA and ATA [8-12], or analysed only a few additional
antibodies [13-17]. The aim of this study was therefore
to characterise all known non-organ-specific, SSc-asso-
ciated autoantibodies, as well as other, potentially new
nuclear autoantibodies by using a standardised protocol
i nt h el a r g eS S cp a t i e n tc o h o r ti n c l u d e di nt h eG e r m a n
Network for Systemic Scleroderma Registry, and to cor-
relate these findings with the clinical characteristics of
these patients.
Materials and methods
Patients
Serum samples from 863 consecutive patients included
in the German Network for Systemic Scleroderma Reg-
istry between 2004 and 2007 from 23 different clinical
centres were analysed. Patient data are gathered and
registered using a consensual registration form and
reference documents with item definitions and recom-
mendations for organ-specific diagnostic procedures as
previously described [18,19]. Of the patients included,
82.9% were female, their mean age ± SD was 58.0 ±
13.4 years (median = 60 years, range 12 to 93). The
patients’ age at disease onset ranged from 3 to 87 years
(median = 49 years, mean = 47.7 ± 14.2).
The registry defines five subsets, that is, limited cuta-
neous and diffuse cutaneous SSc [20], overlap syndrome
[21,22], systemic sclerosis sine scleroderma [23,24] and
undifferentiated connective tissue disease with features
of scleroderma [25,26], as recently described [18]. The
latter subset corresponds largely to the subgroup ‘early
SSc’ as described by LeRoy and Medsger [5] but may
also include patients who will never develop definite
SSc. The study, including the patients’ informed consent
regarding data storage, was approved by the lead Ethics
committee of the Cologne University Hospital and by
the respective ethics committees of the contributing
centres.
Autoantibody analysis
To detect SSc-associated autoantibodies in a compre-
hensive way, we used the search strategy commonly per-
formed in diagnostic procedures for connective tissue
diseases based on a HEp-2 cell immunofluorescence
assay followed by tests using cellular extracts and/or
recombinant antigens. This strategy is focused on circu-
lating antibodies against non-organ-specific cellular
autoantigens. Cell- or tissue-specific autoantibodies,
which have also been described in scleroderma patients
[3], were not included in the analytical protocol. At least
one serum draw from each patient (N = 863) was ana-
lysed for circulating autoantibodies by a predefined pro-
tocol (Figure 1) with at least four assay systems
performed in a single laboratory by a single group of
technologists.
Indirect immunofluorescence using fluorescein iso-
thiocyanate-conjugated goat anti-human immunoglobu-
lin G was performed as a screening method for the
detection of ANAs on HEp-2 cells (HEp-20-10; Euroim-
mun, Lübeck, Germany) seeded onto a microscope slide
[27]. Titres of at least 1:80 dilution were regarded as
positive. Different nuclear and cytoplasmic fluorescence
patterns were documented.
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Page 2 of 14Al i n ei m m u n o a s s a y( E U R O L I N EA N AP r o f i l e3 ;
Euroimmun) was performed according to the manufac-
turer’s instructions. This assay is able to detect, by bind-
ing to recombinant or purified antigens, the following
autoantibodies: U1-ribonucleoprotein (U1-RNP), Sm,
Ro60, Ro52, La (SS-B), Scl-70, PM-Scl, centromere pro-
tein B (CENP-B), proliferating cell nuclear antigen
(PCNA), double-stranded DNA (dsDNA), nucleosomes,
histones, ribosomal P proteins and the mitochondrial
M2 antigen.
Immunoprecipitation (IP) of radiolabelled HeLa cell
extract was performed as described [28,29] with slight
modifications. In brief, HeLa S3 cells in suspension cul-
ture in methionine-deficient RPMI medium with 10%
dialyzed foetal bovine serum were incubated with
35S
methionine (to a final activity of 0.3 MBq/ml) overnight.
They were (1) washed in Tris-buffered saline and (2)
lysed by resuspension in IP buffer (10 mM Tris·HCl, pH
8.0, with 500 mM NaCl, 0.1% Igepal (Sigma, Munich,
Germany) and 2 mM phenylmethylsulfonyl fluoride) and
sonication on ice. IP was performed by incubation of
patient sera (10 μl) with protein A Sepharose beads (2
mg in 500 μl; Sigma) for two hours, three short washing
steps, end-over-end rotation with the radiolabelled cell
extract overnight, five washing steps, separation of the
precipitates on 5% to 20% gradient SDS-PAGE gels and
subsequent autoradiography for six to ten days. Bands
typical of autoantibodies were identified according to
their apparent molecular weight and comigration with
bands produced by reference sera with known autoanti-
body specificity. After we completed this procedure, the
autoantibodies to the following antigens were routinely
detectable: topoisomerase I (Scl-70), RNAPs (I and/or
III), Ku, fibrillarin, To, NOR-90, Pl-7, Pl-12, EJ, OJ, KS,
Mi-2, signal recognition particle, ribonucleoprotein
(usually U1-RNP), SL, PCNA, ribosomal P proteins and
p25/p23, also known as ‘anti-chromo’ [30,31]. In our
hands, the detection of antibodies to Ro, La, PM-Scl, Jo-
1, centromere antigens and the mitochondrial M2 anti-
g e nw a su n r e l i a b l eb yt h i sm e t h o d .B a n d so fu n k n o w n
nature were registered and entered into the database of
autoantibody results.
Immunodiffusion (ID) was performed in Agarose gels
with rabbit and/or calf thymus extract (Pel-Freez Biolo-
gicals, Rogers, AR, USA) as described previously [32].
Autoantibodies were identified by the identity of precipi-
tation lines with patient sera compared with monospeci-
fic prototype sera with known autoantibody specificity.
The use of prototype serum was guided by results of the
immunofluorescence pattern on HEp-2 cells. The fol-
lowing autoantibodies were detectable: topoisomerase 1
(Scl-70), PM-Scl, Ku, SL, Jo-1, Pl-7, U1-RNP, Sm and La
(SS-B). Precipitation bands that did not merge with any
of the prototype sera were registered as unknown auto-
antibodies and entered into the database of autoantibody
results.
In selected sera, confirmatory assays using recombi-
nant or synthetic antigens (see Table 1 Antibody detec-
tion criteria) were performed. More than one serum
sample was available from 213 patients (from 2 to 25
samples). At least one serum sample per patient was
tested with the whole protocol described in Figure 1,
whereas in most cases the follow-up sera drawn were at
least partially characterised with, for example, the HEp-
Figure 1 Protocol for serological analysis of systemic sclerosis patient sera.
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Autoantibody
against
Findings classifying patients as antibody-positive Usual additional findings
Centromere Centromeric immunofluorescence pattern on HEp-2 cells (308 of
310 were positive) or a CENP-B band in line assay (309 of 310
positive)
Topoisomerase
I
At least two of three findings: Scl-70-positive signal in line assay
(258 of 260 positive), a band comigrating with a prototype band
in IP (all positive), a line of identity in ID with the Scl-70
prototype serum (244 of 260 positive)
Typical HEp-2 cell immunofluorescence pattern: fine granular
karyoplasmic, weakly nucleolar, metaphase chromosome-positive
RNA
polymerases
Characteristic IP pattern comigrating with the pattern of a
prototype serum mainly consisting of four bands: Ia, Ib, IIIa and
IIIb [58]
Confirmation by ELISA in 32 of 32 cases with the
immunodominant epitope of RNA polymerase III subunit
RPC155 according to Kuwana et al. [71], provided by Matritec,
Freiburg, Germany. ANA immunofluorescence on HEp-2 cells
was predominantly fine granular only sometimes (five cases) in
addition nucleolar [72].
Fibrillarin An IP band (approximately 34 kDa) comigrating with a
prototype serum band, plus a nucleolar immunofluorescence
pattern on HEp-2 cells
Confirmation by investigational ELISA kindly provided by
Euroimmun, Lübeck, Germany, positive in 11 and borderline in 1
of the 12 cases
To An IP band of approximately 40 kDa plus a nucleolar
immunofluorescence pattern on HEp-2 cells; confirmation by
immunoblot analysis with recombinant To antigen kindly
supplied by Dr M Blüthner, Labor Seelig, Karlsruhe, Germany
PM-Scl A line of identity in ID with a PM-Scl prototype serum (41 of 42
cases) and/or positive result of ELISA with the synthetic peptide
PM-1a [73] (Dr Fooke Laboratorien GmbH, Neuss, Germany) (12
of 13 cases)
Positive reaction in 37 of 41 cases for PM-Scl by line assay. ANA
immunofluorescence on HEp-2 cells usually was nucleolar plus
fine granular karyoplasmic.
Ku Two prominent IP bands at about 70 and 80 kDa comigrating
with prototype bands
In 3 of 10 cases, a line identical to a Ku prototype band in ID.
ANA immunofluorescence was finely granular, usually at a high
titre.
U1-RNP A positive signal for RNP/Sm in line assay, with or without a
positive signal for Sm, plus a typical IP pattern consisting of at
least antigen A (about 33 kDa), antigen B/B’ (about 28/29 kDa)
and antigen C (about 22 kDa)
In 37 of 41 cases, a line of identity with a U1-RNP prototype in
ID. ANA pattern on HEp-2 cells usually was coarsely speckled.
Sm A positive signal for RNP/Sm as well as for Sm in line assay In two of four cases, a band identical to a Sm prototype in ID
with ribonuclease-digested calf thymus extract. IP and
immunofluorescence patterns were similar to those found for
anti-U1-RNP.
Jo-1 A positive signal for Jo-1 in line assay plus a band identical to a
Jo-1 prototype band in ID
Immunofluorescence on HEp-2 cells was inconsistent.
Pl-7 IP band of about 80 kDa comigrating with prototype band plus
a band identical to a Pl-7 prototype band in ID
Cytoplasmic immunofluorescence on HEp-2 cells
OJ Typical triplet band in IP comigrating with prototype bands Cytoplasmic immunofluorescence on HEp-2 cells
U11-RNP
[74,75]
An RNP-like IP pattern and coarsely speckled ANA
immunofluorescence, without any U1-RNP signals in line assay
and ID; U11-RNP specificity detected by C Will and R Lührmann,
Marburg, Germany
p25/p23 [76,77] Doublet IP bands of about 25 and 23 kDa, with the 25 kDa
band comigrating with the precipitate of rabbit anti-p25 kindly
provided by E Chan, Gainesville, FL, USA
HEp-2 cell immunofluorescence pattern was always centromeric
because anti-p25/p23 was exclusively found together with
anticentromere.
SL A band identical to the SL prototype band in ID plus an IP band
at about 31 kDa comigrating with the precipitate of the SL
reference serum
HEp-2 cell immunofluorescence pattern was fine granular, but in
this study often was masked because of other coexisting
antibodies
NOR-90 Doublet IP bands at about 90 kDa comigrating with the
precipitate of a NOR-90 reference serum [78]
The nucleolar immunofluorescence pattern expected on HEp-2
cells was hard to detect in the sera examined in this study,
because NOR-90 antibodies in all cases coincided with other
autoantibodies visible on HEp-2 cells.
Mitochondrial
M2
AMA M2-positive signal by line assay (40 of 41 positive) and/or
AMA typical cytoplasmic immunofluorescence on HEp-2 cells
and/or rat kidney sections (27 of 41 positive)
In IP, a band of around 70 kDa was present in 36 of 41 cases.
Sp100 Multiple nuclear dot pattern on HEp-2 cells [79] plus Sp100
signal in the line assay HUMAN IMTEC-Liver Line Immunoassay
(HUMAN Diagnostics GmbH, Wiesbaden, Germany)
Ro52 Ro52-positive signal by line assay
Ro60 Ro60-positive signal by line assay
La La-positive signal by line assay
AMA = antimitochondrial antibodies; ANA = antinuclear antibodies; CENP-B = centromere protein B; ID = immunodiffusion; IP = immunoprecipitation; PM-Scl =
polymyositis and scleroderma; RNAP = RNA polymerase; RNP = ribonucleoprotein;.
Mierau et al. Arthritis Research & Therapy 2011, 13:R172
http://arthritis-research.com/content/13/5/R172
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autoantibodies are listed in Table 1 together with addi-
tional serological results commonly found and helpful to
identify the antibodies.
In addition to the autoantibodies defined in Table 1
other circulating autoantibodies detected by at least one
of the above-mentioned procedures, either known (for
example, anti-histone, anti-dsDNA) or unknown (for
example, either unidentified bands in IP or ID or anti-
nuclear or anticytoplasmic antibodies on HEp-2 cells
without subsequent identification), were registered. Sera
which were negative for ANAs in immunofluorescence
on HEp-2 cells but exhibited cytoplasmic fluorescence
in that assay and/or a positive signal in any of the other
assays were grouped together as ANA-negative. Sera
without any positive signal, neither defined nor unde-
fined, in all four assay systems described above were
listed as autoantibody-negative.
Statistics
The data were analysed using Microsoft Excel (Microsoft
Corp, Redmond, WA, USA) and SPSS version 14.0 soft-
ware (SPSS, Inc, Chicago, IL, USA) for tabular and gra-
phic representation. Statistical evaluation was performed
using contingency table tests with the help of GraphPad
Prism version 3.02 software (GraphPad, La Jolla, CA,
USA). We calculated OR and 95% CI data. P-values were
calculated using Fisher’s exact test. When multiple tests
were performed, P-values below 0.005 were recorded
without performing strict Bonferroni correction. For
most variables, less than 5% of data were missing. Quan-
titative data (erythrocyte sedimentation rate (ESR), age at
disease onset and Rodnan skin score), depending on the
presence or absence of different autoantibodies, were
analysed using the Mann-Whitney rank-sum test.
Results and discussion
Of the 863 SSc patients studied, 513 (59.4%) were classi-
fied as having limited disease and 173 (20.1%) we classi-
fied as having diffuse cutaneous disease. Another 108
patients (12.5%) had a scleroderma overlap syndrome,
64 (7.4%) had undifferentiated connective tissue disease
with scleroderma features and 5 (0.6%) had systemic
sclerosis sine scleroderma.
The frequency of autoantibodies detected in these
patients is shown in Table 2. Overall, ANAs were
detected in 94.2% of patients. This frequency was similar
to data previously published [12,14,15,33,34] in which
ANA frequencies reported were between 85% and 99%.
Among our patients with ANAs, 86.6% (704 of 813) had
autoantibodies known to be highly associated with SSc,
and among these latter patients, 96.4% (679 of 704) had
antibodies that detected five antigens: centromere,
topoisomerase I, PM-Scl, U1-RNP and RNAPs.
A coincidence of SSc-associated autoantibodies (Table
3) was rare, being detected in only 1.6% patients (11 of
704). The presence of a SSc-associated antibody without
any other autoantibody detectable by the methods used
was found at varying frequencies, being highest for anti-
PM-Scl (73.8%) and lower for, for example, anti-centro-
mere (33.9%) and anti-fibrillarin (33.3%) (see Table 3).
That SSc-associated autoantibodies are largely mutually
exclusive is well-known [14,15,35]. Coincidences in indi-
vidual patients do occur but are rare [33,36,37]. Our
study shows that this statement holds true even if all
known non-organ-specific, SSc-associated autoantibodies
are sought using a rigorous protocol in all patients. On
the other hand, additional (mainly not SSc-specific)
autoantibodies are common and were detected in about
53% in our patient cohort with SSc-associated antibodies
(and in 55.4% of all of our patients). In 14.0% of patients
(n = 121), none of the above-mentioned SSc-associated
but other (defined or undefined) autoantibodies were
found, whereas in 4.4% no autoantibodies at all were
Table 2 Prevalence of autoantibodies in 863 scleroderma
patients
Autoantibodies Patients, n
(%)
Positive for antinuclear antibodies 813 (94.2)
Antibodies highly associated with SSc or scleroderma
overlap syndromes
704 (81.6)
Anti-centromere 310 (35.9)
Anti-topoisomerase I 260 (30.1)
Anti-PM-Scl 42 (4.9)
Anti-U1-RNP 41 (4.8)
Anti-RNA polymerase 33 (3.8)
Anti-fibrillarin 12 (1.4)
Anti-To 2 (0.2)
Anti-Ku 10 (1.2)
Anti-Jo-1/-Pl-7/-OJ 4 (0.5)
Anti-U11-RNP 1 (0.1)
Other autoantibodies
Anti-Ro and/or anti-La 206 (23.9)
Anti-Ro52 187 (21.7)
Anti-Ro60 59 (6.8)
Anti-La 16 (1.9)
Anti-mitochondrial M2 41 (4.8)
Anti-p25/p23 28 (3.2)
Anti-NOR-90 6 (0.7)
Anti-SL 9 (1.0)
Anti-Sm 4 (0.5)
Anti-Sp100 4 (0.5)
Other (known or unknown) 363 (42.1)
Negative for all highly SSc-associated antibodies 159 (18.4)
Negative for antinuclear antibodies 50 (5.8)
Autoantibody-negative by all criteria used 38 (4.4)
ANA = antinuclear antibodies; SSc = systemic sclerosis.
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Antibodies ACA ATA Anti-
PM-Scl
Anti-U1-
RNP
Anti-
RNAP
Anti-
fibrilla-rin
Anti-
To
Anti-
Ku
Anti-Jo-1/
Pl-7/OJ
Anti-U11-
RNP
Anti-
Ro52
Anti-
Ro60
Anti-
La
AMA Anti-
p25/p23
Anti-
NOR-90
Anti-
SL
Anti-
Sm
Anti-
Sp100
Other
ACA 1 0 1 0 0 0 0 0 0 92 11 1 31 28 4 2 0 3 144
ATA 1 2 0 0 0 4 0 0 36 26 6 4 0 1 4 1 0 77
Anti-PM-Scl 0 0 0 0 1 0 0 6 2 0 0 0 0 0 0 0 4
Anti-U1-
RNP
1 0 0 0 0 0 11 6 1 2 0 1 0 4 0 11
Anti-RNAP 0 0 0 0 0 5 1 1 1 0 0 1 0 0 5
Anti-
fibrillarin
00 0 0 0 0 01 0 0 00 0 8
Anti-To 0 0 0 1 1 0 0 0 0 0 0 0 2
Anti-Ku 00 2 2 0 0 0 0 1 0 0 2
Anti-Jo-1/
Pl-7/OJ
03 0 0 0 0 0 0 0 0 1
Anti-U11-
RNP
00 0 00 00 000
Anti-Ro52 41 15 14 11 2 5 2 2 97
Anti-Ro60 14 6 0 0 0 1 1 33
Anti-La 10 00 108
AMA 20 1 1 2 2 9
Anti-p25/
p23
11 01 1 8
Anti-NOR-
90
01 0 4
Anti-SL 003
Anti-Sm 00
Anti-Sp100 2
Other
Isolated
a 104 153 31 19 23 4 0 4 1 1 2 1 0 0 0 0 1 0 0 79
Total
b 310 260 42 41 33 12 2 10 4 1 187 59 16 41 28 6 9 4 4 363
*Number of patients with co-occurrences of autoantibodies.
aIsolated: presence without coincidence of any other autoantibody by all detection methods used.
bTotal number of individuals with the respective
autoantibody; these numbers mostly are smaller than the sum of all co-occurrences plus the ‘isolated’ individuals listed because of some triple, quadruple and higher-order coincidences. ACA = anti-centromere
antibodies; AMA = antimitochondrial antibodies; ATA = anti-topoisomerase I antibodies;; RNAP = RNA polymerase; RNP = ribonucleoprotein.
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4detected by the methods used. Defined autoantibodies
not regarded as SSc-specific, such as anti-Ro/La, anti-
NOR-90 or AMAs rarely occurred without the evidence
of SSc-associated autoantibodies (Table 3). Antibodies
to p25/p23 were detected exclusively in conjunction
with ACA.
From 213 patients, more than one serum sample was
available (from 2 to 25 samples). In the majority (86.4%)
of cases, the results of follow-up testing remained essen-
tially the same and differed in ANA titre by up to only
two titre steps. In 11.3% (24 patients), ANA titre
changes exceeded two steps (up to eight steps), in two
cases ANAs turned negative, in one case the ANA pat-
tern changed from finely granular to nucleolar and in
only two cases new, additional typical SSc autoantibo-
dies emerged.
The detection of antibodies in different disease subsets
is shown in Table 4. It is obvious that ACA and ATA
are not exclusive to either the limited or the diffuse sub-
set. In patients with overlap syndrome, anti-U1-RNP,
anti-PM-Scl and anti-synthetase antibodies are
characteristic.
The correlation of demographic features or signs and
symptoms of SSc with the presence or absence of
defined autoantibodies was investigated by contingency
table analysis. The frequencies of these features and
their positive or negative correlations with specific auto-
antibodies are listed in Table 5. For the purpose of
clarity, only those comparisons that led to P-values
below 0.05 derived by Fisher’s exact test are shown. Sig-
nificance was calculated without correction of P-values
for multiple comparisons, because not all variables used
were independent; however, we are aware of the fact
that some of the weak associations listed in Table 5
might have arisen by chance due to the high number of
comparisons made. Therefore, we focused on those dif-
ferences calculated that were highly significant (P <
0.005; OR printed in bold in Table 5).
Patients with ACA represented 35.9% of all SSc
patients and 38.1% of ANA-positive SSc patients. In
accordance with previous reports [8,9,12,15,33,36,38,39],
these patients were less often male, were older at disease
onset and had a more limited extension of cutaneous
involvement, as documented by a much lower OR for a
Rodnan skin score (RSS) above 10 (Table 5) and by a
very significantly lower mean RSS (Table 6). They had
less involvement of internal organs (pulmonary fibrosis,
cardiac, musculoskeletal and oral involvement), with the
exception of pulmonary hypertension. An association of
ACA with pulmonary hypertension has been observed
in several previous reports [2,12,33,40], but not all of
them [13,36,38,39]. Digital ulcers in our patients with
Table 4 Autoantibodies in different disease subsets in 863 individual systemic sclerosis patients
Limited (N = 513) Diffuse (N = 173) Overlap (N = 108) Undifferentiated (N = 64)
Antibodies n (%) OR
a (P-value) n (%) OR (P-value) n (%) OR (P-value) n (%)
ACA 253 (49.3) 5.00 (P < 0.0001) 12 (6.9) 16 (14.8) 28 (43.8)
ATA 141 (27.5) 98 (56.6) 4.26 (P < 0.0001) 11 (10.2) 9 (14.1)
Anti-RNAP 14 (2.7) 14 (8.1) 3.11 (P = 0.0029) 2 (1.9) 2 (3.1)
Anti-U1-RNP 7 (1.4) 0 (0.0) 31 (28.7) 30.00 (P < 0.0001) 2 (3.1)
Anti-PM-Scl 16 (3.1) 2 (1.2) 22 (20.4) 9.40 (P < 0.0001) 2 (3.1)
Anti-fibrillarin 3 (0.6) 8 (4.6) 8.32 (P = 0.0005) 1 (0.9) 0 (0.0)
Anti-To 1 (0.2) 0 (0) 1 (0.9) 0 (0.0)
Anti-Jo-1/Pl-7/OJ 0 (0.0) 0 (0) 4 (3.7) 65.07 (P = 0.0002) 0 (0.0)
Anti-U11-RNP 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0)
Anti-Ku 5 (1.0) 1 (0.6) 3 (2.8) 1 (1.6)
Anti-SL 5 (1.0) 3 (1.7) 1 (0.9) 0 (0.0)
Anti-Sm 0 (0.0) 0 (0.0) 3 (2.8) 21.54 (P = 0.0069) 0 (0.0)
Anti-NOR-90 5 (1.0) 0 (0.0) 1 (0.9) 0 (0.0)
AMA 28 (5.5) 4 (2.3) 4 (3.7) 5 (7.8)
Anti-Sp100 3 (0.6) 0 (0.0) 0 (0.0) 1 (1.6)
Anti-Ro52 125 (24.4) 1.50 (P = 0.023) 20 (11.6) 27 (25.0) 15 (23.4)
Anti-Ro60 28 (5.4) 14 (8.1) 13 (12.0) 2.11 (P = 0.0382) 4 (6.3)
Anti-La 9 (1.8) 3 (1.7) 1 (0.9) 3 (4.7)
Anti-p25/p23 24 (4.5) 4.25 (P = 0.0031) 0 (0.0) 2 (1.9) 2 (3.1)
Other 209 (40.7) 74 (42.8) 44 (40.7) 34 (53.1)
ANA-negative 32 (6.2) 6 (3.5) 5 (4.6) 7 (10.9)
ACA, anti-centromere antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ATA, anti-topoisomerase I antibodies; RNAP, RNA polymerase;.
aOR for antibody in that subset compared with all other subsets. Only significant positive associations are documented by OR, and those with P-values < 0.005
are printed in bold.
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Page 7 of 14Table 5 Correlations of clinical features with SSc associated autoantibodies
ACA
(310)
ATA
(260)
Anti-PM-
Scl
(42)
Anti-U1-
RNP
(41)
Anti-RNA
-P
(33)
Anti-
Fibrillarin
(12)
Anti-Ku
(10)
Anti-Ro52
(187)
Anti-Ro60
(59)
Anti-La
(16)
AMA
(41)
Anti-p25/
23
(28)
ANA-
negative
(50)
no SSc
associated
ab’s
(161)
male sex
148 (17.1%)
17
0.19 (0.11
to 0.32)
P < 0.0001
64
2.02 (1.4
to 2.91)
p = 0.0002
698 4 2 2 3
0.62 (0.38
to 0.997
p = 0.049
12 2 1 1 10 41
1.90 (1.261
to 2.863)
p = 0,0035
age at disease
onset < 50 y
399/781 (51.1%)
115
0.57 (0.43
to 0.77)
p = 0.0003
135
1.39 (1.02
to 1.88)
p = 0.0431
22 29
2.92 (1.40
to 6.07)
p = 0.0029
13 8 4 77 31 10 20 8 18 73
Rodnan skin
score > 10
294/750 (39.2%)
58
0.27 (0.19
to 0.38)
P < 0.0001
132
3.10 (2.24
to 4.27)
P < 0.0001
14 9 18
3.24 (1.44
to 7.31)
p = 0.0042
7 1 58 23 6 10 11 14 56
Raynaud’s
phenomenon
819 (94.9%)
301
2.26 (1.07
to 4.77)
p = 0.0349
252 37 41 32 12 10 184
3.96 (1.2 to
12.94
p = 0.0133
58 16 41 28 43
0.29 (0.12
to 0.70)
p=
0.0104
140
0.23 (0.12 to
0.42)
P < 0.0001
Digital ulcers
216/840 (25.7%)
55
0.50 (0.36
to 0.71)
P < 0.0001
106
3.18 (2.30
to 4.41)
P < 0.0001
9 11 7 4 1 48 19 6 13 6 4
0.26 (0.09
to 0.76)
p=
0.0076
28
0.60 (0.39 to
0.94)
p = 0.024
Pulmonary
hypertension
126 (14.6%)
57
1.58 (1.08
to 2.32)
p = 0.0208
36 2 9 4 1 0 31 14 2 2 7 2
0.23 (0.06
to 0.97)
p=
0.0232
17
Pulmonary
fibrosis
287 (33.3%)
39
0.18 (0.12
to 0.26)
P < 0.0001
151
4.76 (3.48
to 6.50)
P < 0.0001
16 11 7 2 6 69 30
2.20 (1.29
to 3.75
p = 0.0040
96
0.33 (0.14
to 0.79)
p = 0.01
4
0.33 (0.11
to 0.95)
p = 0.0393
11 55
Lung restrictive
defect
218/833 (26.2%)
41
0.31 (0.21
to 0.45)
P < 0.0001
104
2.96 (2.14
to 4.09)
P < 0.0001
9 7 8 3 4 45 19 4 8 4 10 34
Esophageal
involvement
535 (62.0%)
198 175
1.39 (1.02
to 1.89)
p = 0.039
14
0.29 (0.152
to 0.56)
p = 0.0001
29 20 7 6 120 39 13 24 21 27 87
0.67 (0.47 to
0.94)
p = 0.0243
Proteinuria
90/830 (10.8%)
23
0.56 (0.34
to 0.92)
p = 0.0207
34 4 4 4 1 1 15 9 2 3 1 5 19
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4Table 5 Correlations of clinical features with SSc associated autoantibodies (Continued)
Cardiac
involvement
114 (13.2%)
27
0.51 (0.32
to 0.81)
p = 0.0033
45
1.62 (1.08
to 2.44)
p = 0.0216
575 1 2 2 0 9 1 4 1 52 2
Musculoskeletal
involvement
421/852 (49.4%)
131
0.64 (0.48
to 0.85)
p = 0.0022
130 20 28
2.49 (1.25
to 4.96)
p = 0.009
17 10
5.22 (1.14
to 23.97)
p = 0.0202
68 0
0.71 (0.51
to 0.99)
p = 0.0468
32 12
3.13 (1.002
to 9.79)
p = 0.0447
17 9 25 79
Synovitis
157/837 (18.8%)
35
0.43 (0.29
to 0.65)
P < 0.0001
62
1.71 (1.19
to 2.45)
p = 0.0049
81 3
2.27 (1.14
to 4.53)
p = 0.0326
822 3 2 1 5 5 2
0.21 (0.05
to 0.89)
p=
0.0216
21 0 2 9
Joint
contractures
253/840 (30.1%)
54
0.36 (0.25
to 0.50)
P < 0.0001
107
2.26 (1.65
to 3.08)
P < 0.0001
9 9 10 6 2 49 23 6 9 9 20
1.93 (1.05
to 3.54)
p=
0.0436
56
Tendon friction
rubs
88/840 (10.5%)
14
0.30 (0.16
to 0.53)
P < 0.0001
32 2 5 6 3 1 21 5 2 2 0 6 25
1.95 (1.18 to
3.22)
p = 0.0122
CK elevation
74/835 (8.9%)
14
0.37 (0.21
to 0.68)
p = 0.0009
20 19
3.56 (1.67
to 7.57)
p = 0.0023
56
2.60 (1.03
to 6.55)
p = 0.0485
03
5.32 (1.30
to 21.72)
p = 0.038
21 8 2 1 0 6 16
Sicca syndrome
366/858 (42.7%)
150
1.44 (1.19
to 6.61)
p = 0.0119
98 14 18 12 5 4 96
1.57 (1.13
to 2.17)
p = 0.0075
33
1.85 (1.08
to 3.17)
p = 0.0275
12
4.14 (1.32
to 12.93)
p = 0.0102
19 20
3.50 (1.52
to 8.03)
p = 0.0029
23 66
Mouth
involvement
223/829 (26.9%)
64
0.61 (0.44
to 0.85)
p = 0.0034
93
2.1 (1.53
to 2.93)
P < 0.0001
10 7 10 3 4 49 18 6 11 6 12 34
ESR > 25 mm/h
199/741 (26.9%)
58
0.70 (0.49
to 0.99)
p = 0.046
75
1.55 (1.10
to 2.19)
p = 0.015
4
0.33 (0.11
to 0.94)
p = 0.0325
14 5 0 0 60
1.76 (1.21
to 2.54)
p = 0.0039
28
3.39 (1.92
to 5.97)
P < 0.0001
9
3.62 (1.33
to 9.86)
p = 0.0447
10 5 15 42
ACA, anti-centromere antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ATA, anti-topoisomerase I antibodies; CK, creatine kinase; ESR, erythrocyte sedimentation rate; RNAP = RNA
polymerase; RNP = ribonucleoprotein; SSc, systemic sclerosis. Dichotomous variables are expressed as raw numbers, OR (95% CI) and P values.
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4ACA were less common compared to American patients
[2] and more similar to European [9,12,38] and Japanese
patients [34]. Nevertheless, the presence of ACA does
n o tb ya n ym e a n sp r e c l u d ed i g i t a lu l c e r s .T od a t en o
marker constellation allows the identification of patients
prone to this complication [41-43]. ACAs are frequently
associated with other antibodies, such as anti-Ro
[44-46], anti-mitochondrial (M2) [15,44,47,48] and anti-
p25/p23 [31,49,50] antibodies. These associations were
confirmed by this study. The reasons for this frequent
co-occurrence are unknown. There is no known anti-
genic relationship between the individual targets of the
antibodies. Probably the (unknown) aetiopathogenetic
pathways marked by these antibodies have common
components, including common genetic predispositions.
The prevalence of ATA in our cohort (30.1%) is in
line with the numbers published by others, which have
varied between 13% and 36%
[2,8,9,12,14,15,17,33,34,36,51]. The patients with ATA in
our study were more likely to be male and had higher
RSSs (Tables 5 and 6). More common in this patient
group were digital ulcers, pulmonary fibrosis, dyspnoea,
lung restrictive defect and joint involvement (synovitis,
contractures) as well as mouth involvement. However,
renal involvement, as measured by proteinuria or renal
insufficiency, was not more prevalent in this subgroup, a
finding reported by most other researchers
[8,9,14,15,33,36,51,52] but not all of them [2,34].
The frequency of RNAP antibodies in our cohort was
3.8%, which is at the lower end of the frequency range
reported by others, namely, 10% to 25% in North Amer-
ica [33,52-55], 4% to 31.5% in Europe
[14,16,33,35,56-59] and 5% to 11% in Japan [34,36,60].
This may have several reasons: (1) Our cohort is com-
posed of a broad spectrum of SSc patients, including
patients with milder forms and with overlap or undiffer-
entiated subtypes of the disease, (2) regional differences
due to genetic background and/or environmental influ-
ences and (3) different techniques used to ascertain the
presence of RNAP antibodies. A high mean RSS, reflect-
ing diffuse skin involvement, was evident for patients
with anti-RNAP antibodies (Tables 5 and 6) as pre-
viously observed [2,14,33,34,36,40,54-60]. In addition, we
found creatine kinase (CK) elevation to be more fre-
quently associated with the presence of anti-RNAP anti-
bodies. This has not been noted before; association with
muscular involvement has been found to be nonsignifi-
cant [14,34,40,53,54] or even inverse [2,36,55] in pre-
vious publications. Our result in this study therefore
might be a chance finding due to multiple comparisons.
We did not find any significant positive association of
RNAP antibodies, or any autoantibody evaluated in this
study, with renal involvement. In the German Network
for Systemic Scleroderma Registry, ‘renal involvement’ is
defined as renal insufficiency in the form of decreased
creatinine clearance and/or proteinuria, as well as a con-
sequence of acute renal crisis. The registry did not
include renal crisis as a separate item at that time,
which may underestimate the possible correlation of
antibodies with renal crisis [18]. Within our network,
the frequency of renal crisis currently does not exceed
2% to 3% per year (Hunzelmann N, unpublished obser-
vation). The prevalence of renal crisis among patients
with RNAP antibodies reported in the literature (for
review, see Meyer et al. [57]) varies considerably,
between 0% and 43%.
Antibodies to fibrillarin (U3-RNP) were most promi-
nent in patients with the diffuse subtype (table 4), which
is in accordance with the findings published in previous
reports [2,13,34,40,61]. In fact, patients with anti-fibril-
larin antibodies, on average, had the highest RSS of all
patients in our cohort (Tables 5 and 6). The significance
of this finding, however, is less pronounced because of
the lower number of patients. The detected anti-fibril-
larin antibody frequency of 1.4% was considerably lower
than that reported in previous cohorts (2.5% to 19%)
[2,13,34,36,40,61-63], which may reflect our broad spec-
trum of SSc patients that included patients with overlap
syndrome and undifferentiated forms, as well as
Table 6 Correlations of clinical features with systemic
sclerosis-associated autoantibodies
Quantitative traits Clinical data
Age at disease onset n Mean ± SD (years) P*
Total 781 47.7 (14.2)
Anti-centromere 273 51.3 (12.5) < 0.0001
Anti-topoisomerase I 238 46.0 (14.0) 0.0076
Anti-fibrillarin 12 38.8 (16.0) 0.0404
Anti-U1-RNP 39 38.2 (15.0) < 0.0001
Anti-La 15 37.9 (18.1) 0.0431
Autoantibody-negative 36 52.9 (14.7) 0.0205
Rodnan skin score n Mean score ± SD P
Total 750 10.2 (9.4)
Anti-centromere 275 6.4 (6.0) < 0.0001
Anti-topoisomerase I 227 14.1 (9.7) < 0.0001
Anti-RNA polymerase 27 15.7 (11.7) 0.0091
Anti-fibrillarin 10 21.2 (15.0) 0.0108
Anti-U1-RNP 35 6.9 (9.2) 0.0053
Erythrocyte sedimentation rate n Mean ± SD (mm/hour) P
Total 741 19.46 (16.7)
Anti-topoisomerase I 227 22.95 (19.1) 0.0002
Anti-PM-Scl 36 12.19 (9.4) 0.0014
Anti-Ro52 167 22.05 (18.8) 0.0374
Anti-Ro60 53 28.47 (19.6) < 0.0001
Anti-La 16 28.56 (20.1) 0.0447
PM-Scl = polymyositis and scleroderma; RNP = ribonucleoprotein; SSc,
systemic sclerosis. *P-value calculated by Mann-Whitney rank-sum test for
comparison of antibody-positive vs antibody-negative patients.
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Page 10 of 14methodological differences and/or the central European
background of the patients. Ethnic heterogeneity with a
higher frequency of anti-fibrillarin antibodies in black
patients has been described previously [2,13,40,61-63].
Our findings of a lower age at disease onset and a
higher prevalence of musculoskeletal involvement
(Tables 5 and 6) are in line with most previous results
[2,36,61,63].
The frequency of PM-Scl antibodies (4.9%) detected in
our cohort is in accord with previously published studies
in which frequencies between 2% and 6% were noted for
SSc patients [1-3,17,33]. These antibodies are most well-
known as being typical in patients with dermatomyosi-
tis-scleroderma overlap syndrome [1,3]. Accordingly, CK
elevation was highly associated with anti-PM-Scl in our
cohort. On the other hand, these patients were markedly
less likely to have oesophageal involvement (Table 5)
and had a low mean ESR (Tables 5 and 6). We found
elevated ESR levels in an earlier series of SSc patients
with anti-PM-Scl antibodies [32], but others, to the best
of our knowledge, did not. (Patients with anti-PM-Scl
have rarely been analysed in the large SSc series
reported previously.) Therefore, this finding has to be
reproduced by independent work in the future. That
these patients have a relatively benign prognosis has
been mentioned several times before [64-66]. Accord-
ingly, 31% of our patients with anti-PM-Scl antibodies
were devoid of any internal organ involvement, com-
pared with 13% of the patients without anti-PM-Scl (P =
0.0023, data not shown).
Antibodies to Ku, when found in SSc patients, are
often associated with scleroderma overlap syndrome and
with muscular involvement [17,36]. Accordingly, we
registered a high OR, but with low significance because
of the relatively low patient number, for CK elevation
associated with anti-Ku antibody (Table 5). The com-
plete absence of ACA and the occasional presence of
ATA described in a large previous study that focused on
anti-Ku in patients with SSc [17] were nicely reproduced
in our cohort (Table 3). Most of our anti-Ku sera (7 of
10) were positive only by IP and negative in a ‘classical’
precipitation test with native antigen. In a previous
study, on the contrary, a similar test (counterimmunoe-
lectrophoresis) was even more sensitive than a line assay
to anti-Ku. A possible explanation for this discrepancy
might be the source of the antigen, which was of rabbit
origin, in our ID assay. Ku autoantibodies are known to
tend to be nonreactive with nonhuman antigens [67].
Antibodies to p25/p23 (’anti-chromo’) characterise a
patient subset within the group of ACA-positive SSc
patients. The clinical findings among these patients were
heterogeneous in previous reports. Soriano et al. [49]
found an elevated prevalence of erosive arthritis and
Furuta et al. [50] reported more interstitial lung disease
and liver involvement, whereas Japanese groups
[30,31,68] discovered cytopenias, Sjögren’ss y n d r o m e ,
overlap with systemic lupus erythematosus and higher
ESR levels. We confirmed the relatively strong associa-
tion with Sjögren’s syndrome on the basis of our finding
that 20 (71.4%) of 28 patients with p25/p23 antibodies
had sicca symptoms, compared to only 41.7% of SSc
patients who were negative for these autoantibodies
(Table 5). In fact, the weak association of ACA with
sicca symptoms (OR = 1.44) (Table 5) lost significance
when those patients with co-occurring anti-p25/p23
were eliminated. Likewise, the low mean RSS calculated
for ACA-positive patients (6.4) (see Table 6) turned
even lower (6.2) after exclusion of patients with anti-
p25/p23.
Antibodies to Ro and/or La, as expected and as pre-
viously reported [44,45,69,70], were associated with
sicca syndrome. This association was only marginally
significant; in fact, the antibodies with the most promi-
nent association with the sicca complex were, as men-
tioned above, anti-p25/p23 antibodies. Anti-Ro and/or
anti-La antibodies showed a particularly high correla-
tion with elevated ESR (Tables 5 and 6). An unexpect-
edly strong association of anti-Ro60 with pulmonary
fibrosis (Table 5) was mainly secondary to the rela-
tively high co-occurrence of this antibody with ATA
(see Table 3).
No highly significant differences for any of the autoan-
tibody-defined subgroups could be found for gastric,
intestinal or renal involvement, including hypertension
and reduced renal function. Furthermore, no significant
differences dependent on antibodies against aminoacyl-
transfer RNA synthetases, To, Sm, SL or NOR-90 were
detected, probably because of the low numbers of
patients positive for these antibodies. Patients without
highly SSc-associated antibodies were more often male
and less frequently had Raynaud’s phenomenon.
Conclusions
The occurrence of SSc-related autoantibodies has never
been analysed in such detail in a cohort as large as this
one. We have shown that five antigens appear to be suf-
ficient to detect more than 95% of the known SSc-asso-
ciated autoantibody responses in ANA-positive SSc
patients. In more than half of patients with a SSc-asso-
ciated antibody, other nuclear autoantibodies were
detected and a considerable patient group (around 40%)
still displayed uncharacterised ANAs of as yet unknown
significance.
To the best of our knowledge, this is the largest com-
prehensive analysis of the presence of SSc-associated as
well as other non-organ-specific autoantibodies in SSc
patients that was performed in a single central labora-
tory and demonstrates the complexity and heterogeneity
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Page 11 of 14of the autoimmune response underlying the pathogen-
esis of this still enigmatic disease.
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